Improved survival of young donor age dopamine grafts in a rat model of Parkinson's disease

Neuroscience

Volumn 146, Issue 4, 2007, Pages 1606-1617

  Torres, E M ^a   Monville, C ^b   Gates, M A ^c   Bagga, V ^a   Dunnett, S B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b I Stem   (France)

^c KEELE UNIVERSITY   (United Kingdom)

Author keywords

6 OHDA; donor age; dopamine grafts; Parkinson's disease

Indexed keywords

DOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; FOREBRAIN; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SURVIVAL;

AGE FACTORS; AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN TISSUE TRANSPLANTATION; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; EMBRYO; FEMALE; MESENCEPHALON; NEURONS; PARKINSON DISEASE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; TRANSPLANTS; TYROSINE 3-MONOOXYGENASE;

EID: 34248996634     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.03.037     Document Type: Article

References (67)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 94 (1946) 239-247
2. Ambrus A., Kraftsik R., and Barakat-Walter I. Ontogeny of calretinin expression in rat dorsal root ganglia. Brain Res Dev Brain Res 106 (1998) 101-108
3. Barker R.A. Repairing the brain in Parkinson's disease: where next?. Mov Disord 17 (2002) 233-241
4. Barker R.A., Fricker R.A., Abrous D.N., Fawcett J., and Dunnett S.B. A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplant 4 (1995) 173-200
5. Bartlett J.S., Samulski R.J., and McCown T.J. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 9 (1998) 1181-1186
6. Bjorklund A., Dunnett S.B., Brundin P., Stoessl A.J., Freed C.R., Breeze R.E., Levivier M., Peschanski M., Studer L., and Barker R. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2 (2003) 437-445
7. Bjorklund A., Dunnett S.B., Stenevi U., Lewis M.E., and Iversen S.D. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res 199 (1980) 307-333
8. Bolam J.P., Freund T.F., Bjorklund A., Dunnett S.B., and Smith A.D. Synaptic input and local output of dopaminergic neurons in grafts that functionally reinnervate the host neostriatum. Exp Brain Res 68 (1987) 131-146
9. Borlongan C.V., and Sanberg P.R. Neural transplantation for treatment of Parkinson's disease. Drug Discov Today 7 (2002) 674-682
10. Briscoe J., and Ericson J. Specification of neuronal fates in the ventral neural tube. Curr Opin Neurobiol 11 (2001) 43-49
11. Brundin P., Isacson O., and Bjorklund A. Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. Brain Res 331 (1985) 251-259
12. Brundin P., Karlsson J., Emgard M., Schierle G.S., Hansson O., Petersen A., and Castilho R.F. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 9 (2000) 179-195
13. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., and Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazeroids in Parkinson's disease. Brain 123 Pt 7 (2000) 1380-1390
14. Butler H., and Juurlink B.H.J. An atlas for staging mammalian and chick embryos (1987), CRC Press, Boca Raton, FL
15. Carvey P.M., Ling Z.D., Sortwell C.E., Pitzer M.R., McGuire S.O., Storch A., and Collier T.J. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp Neurol 171 (2001) 98-108
16. Cenci M.A., and Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99 (2006) 381-392
17. Chaturvedi R.K., Shukla S., Seth K., and Agrawal A.K. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Neurosci Lett 398 (2006) 44-49
18. Cohen B.R., and Sladek C.D. Expression of floor plate in dispersed mesencephalic cultures: role in differentiation of tyrosine hydroxylase neurons. Exp Neurol 147 (1997) 525-531
19. Doucet G., Murata Y., Brundin P., Bosler O., Mons N., Geffard M., Ouimet C.C., and Bjorklund A. Host afferents into intrastriatal transplants of fetal ventral mesencephalon. Exp Neurol 106 (1989) 1-19
20. Dunnett S.B., Torres E.M., Gates M.A., and Fricker-Gates R.A. Transplantation. In: Etilsumak T., and Fischer M. (Eds). Handbook of experimental neurology (2006), University Press, Cambridge 269-307
21. Dunnett S.B. Transplantation of embryonic dopamine neurons: what we know from rats. J Neurol 238 (1991) 65-74
22. Dunnett S.B., and Bjorklund A. Basic neural transplantation techniques. I. Dissociated cell suspension grafts of embryonic ventral mesencephalon in the adult rat brain. Brain Res Brain Res Protoc 1 (1997) 91-99
23. Dunnett S.B., Bjorklund A., and Lindvall O. Cell therapy in Parkinson's disease: stop or go?. Nat Rev Neurosci 2 (2001) 365-369
24. Dunnett S.B., Bjorklund A., Schmidt R.H., Stenevi U., and Iversen S.D. Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol Scand Suppl 522 (1983) 39-47
25. Dunnett S.B., Whishaw I.Q., Rogers D.C., and Jones G.H. Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-hydroxydopamine lesions. Brain Res 415 (1987) 63-78
26. Farkas L.M., Dunker N., Roussa E., Unsicker K., and Krieglstein K. Transforming growth factor-beta(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo. J Neurosci 23 (2003) 5178-5186
27. Freed C.R. Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease?. Proc Natl Acad Sci U S A 99 (2002) 1755-1757
28. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., and Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
29. Fricker-Gates R.A., Lundberg C., and Dunnett S.B. Neural transplantation: restoring complex circuitry in the striatum. Restor Neurol Neurosci 19 (2001) 119-138
30. Gates M.A., Torres E.M., White A., Fricker-Gates R.A., and Dunnett S.B. Re-examining the ontogeny of substantia nigra dopamine neurons. Eur J Neurosci 23 (2006) 1384-1390
31. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Odin P., Wenning G.K., Morrish P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Quinn N.P., and Lindvall O. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 122 Pt 6 (1999) 1121-1132
32. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., and Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56 (1999) 179-187
33. Hynes M., Poulsen K., Tessier-Lavigne M., and Rosenthal A. Control of neuronal diversity by the floor plate: contact-mediated induction of midbrain dopaminergic neurons. Cell 80 (1995) 95-101
34. Isacson O. The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol 2 (2003) 417-424
35. Kordower J.H., Goetz C.G., Freeman T.B., and Olanow C.W. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol 144 (1997) 41-46
36. Lindvall O. Stem cells for cell therapy in Parkinson's disease. Pharmacol Res 47 (2003) 279-287
37. Lindvall O., and Bjorklund A. Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials. Acta Neurol Scand Suppl 126 (1989) 197-210
38. Lindvall O., and Hagell P. Cell therapy and transplantation in Parkinson's disease. Clin Chem Lab Med 39 (2001) 356-361
39. Lindvall O., Sawle G., Widner H., Rothwell J.C., Bjorklund A., Brooks D., Brundin P., Frackowiak R., Marsden C.D., and Odin P. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 35 (1994) 172-180
40. Madrazo I., Leon V., Torres C., Aguilera M.C., Varela G., Alvarez F., Fraga A., Drucker-Colin R., Ostrosky F., and Skurovich M. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N Engl J Med 318 (1988) 51
41. Nguyen J.P., Rémy P., Palfi S., Keravel Y., Peschanski M., and Césaro P. Bilateral intrastriatal grafts of fetal mesencephalic neurons in Parkinson's disease: long-term results in 9 patients. Mov Disord 15 Suppl 3 (2000) 53-54
42. Nikkhah G., Olsson M., Eberhard J., Bentlage C., Cunningham M.G., and Bjorklund A. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 63 (1994) 57-72
43. O'Keeffe G.W., and Sullivan A.M. Donor age affects differentiation of rat ventral mesencephalic stem cells. Neurosci Lett 375 (2005) 101-106
44. Olanow C.W., Freeman T.B., and Kordower J.H. Neural transplantation as a therapy for Parkinson's disease. Adv Neurol 74 (1997) 249-269
45. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., and Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
46. Olanow C.W., Kordower J.H., and Freeman T.B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19 (1996) 102-109
47. Olson L., Cheng H., Zetterstrom R.H., Solomin L., Jansson L., Gimenez-Llort L., Hoffer B.J., and Perlmann T. On CNS repair and protection strategies: novel approaches with implications for spinal cord injury and Parkinson's disease. Brain Res Brain Res Rev 26 (1998) 302-305
48. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd edition (2003), Academic Press, London
49. Peschanski M. 10 Years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future. J Soc Biol 195 (2001) 51-55
50. Piccini P., Pavese N., Hagell P., Reimer J., Bjorklund A., Oertel W.H., Quinn N.P., Brooks D.J., and Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128 (2005) 2977-2986
51. Rosenblad C., Kirik D., and Bjorklund A. Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport 10 (1999) 1783-1787
52. Rosenblad C., Martinez-Serrano A., and Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75 (1996) 979-985
53. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., Widmer H.R., and Zurn A.D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol 149 (1998) 230-236
54. Schmidt R.H., Bjorklund A., and Stenevi U. Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res 218 (1981) 347-356
55. Schmidt R.H., Bjorklund A., Stenevi U., Dunnett S.B., and Gage F.H. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol Scand Suppl 522 (1983) 19-28
56. Seiger A., and Olson L. Late prenatal ontogeny of central monoamine neurons in the rat: Fluorescence histochemical observations. Z Anat Entwicklungsgesch 140 (1973) 281-318
57. Shinoda M., Hudson J.L., Stromberg I., Hoffer B.J., Moorhead J.W., and Olson L. Microglial cell responses to fetal ventral mesencephalic tissue grafting and to active and adoptive immunizations. Exp Neurol 141 (1996) 173-180
58. Sinclair S.R., Fawcett J.W., and Dunnett S.B. Dopamine cells in nigral grafts differentiate prior to implantation. Eur J Neurosci 11 (1999) 4341-4348
59. Sortwell C.E. Strategies for the augmentation of grafted dopamine neuron survival. Front Biosci 8 (2003) S522-S532
60. Sullivan A.M., Pohl J., and Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur J Neurosci 10 (1998) 3681-3688
61. Takayama H., Ray J., Raymon H.K., Baird A., Hogg J., Fisher L.J., and Gage F.H. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med 1 (1995) 53-58
62. Torres E.M., Monville C., Lowenstein P.R., Castro M.G., and Dunnett S.B. Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors: Increased yield of dopamine cells is dependent on embryonic donor age. Brain Res Bull 68 (2005) 31-41
63. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24 (1970) 485-493
64. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., Bjorklund A., Lindvall O., and Langston J.W. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327 (1992) 1556-1563
65. Winkler C., Sauer H., Lee C.S., and Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16 (1996) 7206-7215
66. Yasuhara T., Matsukawa N., Hara K., Yu G., Xu L., Maki M., Kim S.U., and Borlongan C.V. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J Neurosci 26 (2006) 12497-12511
67. Yurek D.M. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 153 (1998) 195-202